Biogen Secures First-Round Patent Win For Tecfidera; One More To Go
Executive Summary
PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.
You may also be interested in...
Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes
ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.
Biogen Staying "Laser-Focused" On Neuroscience
The company is under pressure from investors to add new pipeline assets, but stronger than expected initial sales of Spinraza helped to assuage near-term growth concerns.
Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation
Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.